No Data
CSPC Innovation Pharmaceutical (300765.SZ): The antibody-drug conjugate SYS6043 from Giant Stone Bio has been approved for clinical trials.
On December 20, Glorun announced that CSPC Innovation Pharmaceutical (300765.SZ) disclosed that its subsidiary CSPC PHARMA Giant Stone Biological Pharmaceutical Co., Ltd. (referred to as "Giant Stone Biological") recently received the approval from the National Medical Products Administration for the "Clinical Trial Approval Notice" concerning SYS6043, which will soon commence clinical trials. SYS6043 is a monoclonal antibody-drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. SYS6043 is classified as a Class 1 Biological Product for therapeutic use.
Those Who Invested in CSPC Innovation Pharmaceutical (SZSE:300765) Five Years Ago Are up 406%
CSPC Innovation Pharmaceutical Get US FDA Fast Track Qualification for Cervical Cancer Drug
Cspc innovation pharmaceutical (300765.SZ): The holding subsidiary's authorized drug has obtained the usa FDA fast track designation.
格隆汇Dec 4th | CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlling subsidiary CSPC Pharma Group's Jushi Biopharmaceutical Co., Ltd. authorized Corbus Pharmaceuticals, Inc. (hereinafter referred to as "Corbus") to develop CRB-701 (SYS6002), which has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of recurrent or refractory metastatic cervical cancer. The product is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, containing a site-specific cleavable linker, allowing for
cspc innovation pharmaceutical (300765.SZ): The application for the上市 of the ustekinumab injection by Giant Stone Biotechnology has been accepted.
On November 26, Gelonghui reported that cspc innovation pharmaceutical (300765.SZ) announced that its holding subsidiary cspc pharma Giant Stone Biopharmaceutical Co., Ltd. (hereinafter referred to as "Giant Stone Bio") recently received the "Acceptance Notification" issued by the National Medical Products Administration, and the market application for Ustekinumab injection has been accepted. Ustekinumab injection is a fully human IgG1κ monoclonal antibody that acts as an IL-12/IL-23p40 inhibitor; Ustekinumab specifically binds to the p40 protein subunit of IL-12 and IL-23 with high affinity, blocking IL-12 and IL-23.
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) Market Cap Dropped CN¥3.3b Last Week; Public Companies Bore the Brunt
